Health Care/Hospital

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- October 20, 2025- Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted another breakthrou...

2025-10-20 13:21 1136

Alphamab Oncology Presented Multiple Clinical Data on Biparatopic HER2-targeting ADC JSKN003 at ESMO Congress 2025

SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ovarian cancer (OC) and HER2-positive metastatic colore...

2025-10-20 13:15 1250

Positive Results from Phase 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan Presented at ESMO Presidential Symposium and Simultaneously Published in NEJM

CHENGDU, China, Oct. 20, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, results from a Phase 3 OptiTROP-Lung04 trial of the Company's trophoblast cell-s...

2025-10-20 10:36 1184

Antengene Presents Latest ATG-022 Clinical Data at ESMO 2025 Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability

SHANGHAI and HONG KONG, Oct. 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...

2025-10-20 09:00 1117

Ascletis Completes Enrollment in U.S. Phase IIa Study for Its Once-Monthly Subcutaneous Depot Treatment Formulation of Small Molecule GLP-1R Agonist ASC30 for Obesity

-          The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) ofsmall molecule GLP-1 receptor (GLP-1R) agonist ASC30  in 65 participants with obesity or overweight. -          The ult...

2025-10-20 08:10 1410

Multitude Therapeutics Announces Encouraging Interim Phase I/II Results from Ongoing First-in-Human Study Evaluating its MUC18-directed Antibody-Drug-Conjugate, AMT-253, in Melanoma and Other Advanced Solid Tumors at the 2025 ESMO Annual Meeting

AMT-253 is a potential first-in-class MUC18-directed ADC with a proprietary linker-payload design   AMT-253 demonstrated a manageable safety profile, consistent with other TOP1-inhibitor based ADCs Promising antitumor activity was observed in heavily pretreated patients with melanoma and gyneco...

2025-10-19 15:00 2597

From Wellbeing to Academics: Why HK Parents Are Hitting Pause on Kids' Social Media and Device Use

Look Up Hong Kong-Ipsos survey of 651 parents backs a four-part plan for kids' wellbeing: delayed access to smartphones and social media, phone-free schools and more real-world activity and experiences.  HONG KONG, Oct. 19, 2025 /PRNewswire/ -- Look Up Hong Kong, a new parent-led group launched ...

2025-10-19 13:00 1861

Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO

CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held inBerlin, Germany, results from a Phase 3 OptiTROP-Breast02 study of the Company's trophoblast cel...

2025-10-18 22:46 2150

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

SUZHOU, China, Oct. 18, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the first interim analysis results of a phase III clinical trial of anbenitamab injection (KN026), independently developed by the Company and co-developed with JMT-Bio Technology Co., Ltd., a wholl...

2025-10-18 14:59 2138

SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025

SINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation of first-in-human clinical data for SCG142 in an investigato...

2025-10-18 13:00 2522

One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions

GUANGZHOU, China, Oct. 18, 2025 /PRNewswire/ -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune...

2025-10-18 11:06 2318

NYSE Content Advisory: Pre-Market Update + Automakers await 5-year tariff relief extension

NEW YORK, Oct. 17, 2025 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins.    NYSE Content Advisory: Pre-Market Update + Automakers await 5-ye...

2025-10-17 20:55 2258

Kelun-Biotech's Core product Trastuzumab Botidotin Approved for Marketing by NMPA for HER2-positive BC

CHENGDU, China, Oct. 17, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's human epidermal growth factor receptor 2 (HER2)-directed antibody-drug conjugate (ADC) trastuzumab botidotin (also known as A166)  was approved for marketi...

2025-10-17 20:22 1899

One Heung Kong released the White Paper on Global Sustainable and Healthy Living Environments jointly with other institutions

GUANGZHOU, China, Oct. 17, 2025 /PRNewswire/ -- On October 14, the 2025 Global Engineering Conference and the first World Green Design Conference opened in Shanghai, China, drawing together over 250 former senior UN officials, academicians from different countries, and representatives from Fortune...

2025-10-17 18:39 1772

HMI Medical Signs MOA With Ibraco Berhad To Acquire Land For The Establishment Of Its Third Hospital In Malaysia

The new tertiary hospital will be located within the NorthBank Township in Kuching,Sarawak and is targeted to launch in 2029 SINGAPORE, Oct. 17, 2025 /PRNewswire/ -- Health Mangement International Pte Ltd ("HMI Medical") has signed a Memorandum of Agreement ("MoA") with KLSE listed andSarawak-ba...

2025-10-17 16:49 1569

RITFIT Supports Breast Cancer Awareness Through Fitness at Making Strides Against Breast Cancer Walk

Home fitness brand RITFIT highlights women's empowerment and health advocacy with its Pink Series collection CHINO HILLS, Calif., Oct. 17, 2025 /PRNewswire/ -- RITFIT, a leading home fitness brand dedicated to empowering women through strength and wellness, sponsored and participated in the Maki...

2025-10-17 16:11 913

Chula Launches Newborn Genome Sequencing Project for Early Detection and Prevention of Genetic Diseases

BANGKOK, Oct. 17, 2025 /PRNewswire/ -- The Center of Excellence in Medical Genetics ,Faculty of Medicine , Chulalongkorn University

2025-10-17 16:00 1374

I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences

* New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide * Intention to pursue a Hong Kong initial public offering (IPO) to expand ...

2025-10-17 15:21 2479

/C O R R E C T I O N -- Siemens Healthineers/

In the news release, NUH And NUS Launch New Molecular Imaging And Theranostic Centre To Strengthen Patient Care And Research, issued16-Oct-2025 by Siemens Healthineers over PR Newswire, we are advised by the company that the headline and 1st paragraph have been updated; all instances of Molecular...

2025-10-17 14:49 2411

Wang Qunbin: Innovation-Driven, Fosun's Path to Globalization

HONG KONG, Oct. 17, 2025 /PRNewswire/ -- On 16 October, the 2025 Sustainability Global Leaders Conference was held inShanghai. Themed "Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth", the Conference brought together approximately 500 guests fromChina and ab...

2025-10-17 11:17 2212
1 ... 21222324252627 ... 551

Week's Top Stories